FT
| |
Franklin Templeton SMACS Series E | FQTEXMutual Fund | |
| Franklin Templeton SMACS Series E | |
| Last update 2024-07-23 | 41 Stocks (11 new) |
| Value $84.00 Mil | Turnover 28 % |
| Portfolio Report | |
Franklin Templeton SMACS Serie... Top Holdings of 2024-05-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK | Merck & Co Inc | 45,000 | 5649.300 | 0% | 6.700 | 0% | 0.000 | -9.06% | +9.50% | 297003.611 | Drug Manufacturers | |
JNJ | Johnson & Johnson | 33,000 | 4840.110 | New Holding | 5.740 | +5.74% | 0.000 | +11.80% | +7.07% | 395173.122 | Drug Manufacturers | |
ADI | Analog Devices Inc | 20,000 | 4689.800 | 0% | 5.560 | 0% | 0.000 | -0.77% | +15.70% | 112629.542 | Semiconductors | |
APD | Air Products & Chemicals Inc | 17,000 | 4533.900 | +70.00% | 5.380 | +2.22% | 0.010 | +6.23% | +6.34% | 64022.133 | Chemicals | |
KO | Coca-Cola Co | 65,000 | 4090.450 | 0% | 4.850 | 0% | 0.000 | +16.04% | +24.37% | 308758.956 | Beverages - Non-Alcoholic | |
PM | Philip Morris International Inc | 35,000 | 3548.300 | 0% | 4.210 | 0% | 0.000 | +20.77% | +31.71% | 187804.478 | Tobacco Products | |
RIO | Rio Tinto PLC | 50,000 | 3505.000 | 0% | 4.160 | 0% | 0.000 | -2.19% | -8.46% | 102682.922 | Metals & Mining | |
ORCL | Oracle Corp | 25,000 | 2929.750 | -32.43% | 3.480 | -1.78% | 0.000 | +17.80% | +60.81% | 465522.623 | Software | |
PFE | Pfizer Inc | 100,000 | 2866.000 | New Holding | 3.400 | +3.40% | 0.000 | +7.39% | +6.61% | 166714.168 | Drug Manufacturers | |
C | Citigroup Inc | 41,500 | 2585.870 | 0% | 3.070 | 0% | 0.000 | +3.50% | +24.21% | 118550.393 | Banks |
Franklin Templeton SMACS Series E's Historical Top Holdings Breakdowns
Franklin Templeton SMACS Series E's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 2024-05-31 | New Buy | +5.74% | 144.38 ($152.19) 162.74 | $164.16 | 7.87% | New holding | 33,000 | 33,000 | |
AZN | AstraZeneca PLC | 2024-05-31 | Sold Out | -5.10% | 64.79 ($71.32) 79.18 | $78.38 | 9.90% | Sold Out | 0 | -60,000 | |
NSRGY | Nestle SA | 2024-05-31 | Sold Out | -4.83% | 99.65 ($103.94) 108.75 | $97.10 | -6.58% | Sold Out | 0 | -35,000 | |
XSWX:ROG | Roche Holding AG | 2024-05-31 | Sold Out | -4.51% | 214.1 (CHF227.53) 244.75 | CHF267.50 | 17.57% | Sold Out | 0 | -13,000 | |
TXN | Texas Instruments Inc | 2024-05-31 | Sold Out | -3.77% | 159.68 ($177.72) 202.54 | $203.34 | 14.42% | Sold Out | 0 | -17,000 | |
PFE | Pfizer Inc | 2024-05-31 | New Buy | +3.40% | 25.26 ($27.35) 29.6 | $29.42 | 7.57% | New holding | 100,000 | 100,000 | |
SHEL | Shell PLC | 2024-05-31 | Reduce | -2.92% | 62.85 ($70.03) 74.17 | $68.72 | -1.87% | Reduce -53.85% | 30,000 | -35,000 | |
ABBV | AbbVie Inc | 2024-05-31 | New Buy | +2.49% | 154.79 ($168.87) 182.1 | $193.47 | 14.57% | New holding | 13,000 | 13,000 | |
APD | Air Products & Chemicals Inc | 2024-05-31 | Add | +2.22% | 227.76 ($244.35) 266.7 | $287.98 | 17.86% | Add 70% | 17,000 | 7,000 | |
PEP | PepsiCo Inc | 2024-05-31 | New Buy | +2.05% | 162.04 ($172.73) 183.11 | $171.18 | -0.90% | New holding | 10,000 | 10,000 |
Franklin Templeton SMACS Series E Total Holding History ($B)
Franklin Templeton SMACS Series E's Asset Allocation
Franklin Templeton SMACS Series E Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Franklin Templeton SMACS Series E's Hypothetical Growth since 2024-05-31
Franklin Templeton SMACS Series E's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Franklin Templeton SMACS Series E's Holdings Heat Map
Size field:
Franklin Templeton SMACS Series E's Holdings Bubble Chart
Franklin Templeton SMACS Series E News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers